2024MAY10: Our hosting provider is experiencing intermittent networking issues. We apologize for any inconvenience.

Searching across hundreds of databases

Our searching services are busy right now. Your search will reload in five seconds.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

Rescue of PFOS-induced human Sertoli cell injury by overexpressing a p-FAK-Y407E phosphomimetic mutant.

Scientific reports | 2017

PFOS induces Sertoli cell injury using testicular cells isolated from rodent testes, but it remains unknown if PFOS has similar effects in humans. Herein, we maintained human Sertoli cells in a mitotically active state in vitro, thus enabling transfection experiments that altered gene expression to explore the molecular mechanism(s) underlying toxicant-induced cell injury. Human Sertoli cells obtained from men at ages 15, 23, 36 and 40 were cultured in vitro. These differentiated Sertoli cells remained mitotically active when cultured in the presence of 10% FBS (fetal bovine serum), with a replication time of ~1-3 weeks. At ~80% confluency, they were used for studies including toxicant exposure, immunoblotting, immunofluorescence analysis, tight junction (TJ)-permeability assessment, and overexpression of BTB (blood-testis barrier) regulatory genes such as FAK and its phosphomimetic mutants. PFOS was found to induce Sertoli cell injury through disruptive effects on actin microfilaments and microtubule (MT) organization across the cell cytosol. As a consequence, these cytoskeletal networks failed to support cell adhesion at the BTB. Overexpression of a FAK phosphomimetic and constitutively active mutant p-FAK-Y407E in these cells was capable of rescuing the PFOS-induced injury through corrective cellular organization of cytoskeletal elements.

Pubmed ID: 29150642 RIS Download

Associated grants

  • Agency: NICHD NIH HHS, United States
    Id: R01 HD056034
  • Agency: NICHD NIH HHS, United States
    Id: U54 HD029990

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


Thermo Fisher Scientific (tool)

RRID:SCR_008452

Commercial vendor and service provider of laboratory reagents and antibodies. Supplier of scientific instrumentation, reagents and consumables, and software services.

View all literature mentions

Scion Image (tool)

RRID:SCR_008673

THIS RESOURCE IS NO LONGER IN SERVICE, documented on July 17, 2013. Commercial software vendor.

View all literature mentions

GENEWIZ (tool)

RRID:SCR_003177

Commercial organization for research and development genomics services and technical support to researchers.

View all literature mentions

Goat Anti-Actin Polyclonal antibody, Unconjugated (antibody)

RRID:AB_630836

This polyclonal targets ACTG1, ACTC1, ACTA1, ACTA2, ACTG2, ACTB

View all literature mentions

bovine anti-mouse IgG-HRP (antibody)

RRID:AB_634824

This polyclonal targets bovine anti-mouse IgG-HRP

View all literature mentions

bovine anti-rabbit IgG-HRP (antibody)

RRID:AB_634837

This polyclonal targets Rabbit IgG

View all literature mentions

N-cadherin Monoclonal Antibody (3B9) (antibody)

RRID:AB_2313779

This monoclonal targets N-cadherin

View all literature mentions

Eps8 (antibody)

RRID:AB_397544

This monoclonal targets Eps8

View all literature mentions

EB1 (H-70) (antibody)

RRID:AB_2141629

This polyclonal targets MAPRE1

View all literature mentions

Goat Anti-Actin Polyclonal antibody, Unconjugated (antibody)

RRID:AB_630836

This polyclonal targets ACTG1, ACTC1, ACTA1, ACTA2, ACTG2, ACTB

View all literature mentions

Goat Anti-Actin Polyclonal antibody, Unconjugated (antibody)

RRID:AB_630836

This polyclonal targets ACTG1, ACTC1, ACTA1, ACTA2, ACTG2, ACTB

View all literature mentions